Live Breaking News & Updates on Robust Suppression

Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks BOST. ....

United States , Marcus Maurer , Andrea Matthews , Jillc Milne , Instagram Astriatx , Astria Therapeutics Inc , Corporate Communications , American Academy Of Allergy , Office At Astria , Neither The Company , Drug Administration , Business Development , Exchange Commission , Initial Proof Of Concept Results Anticipated , Once Every Three , Six Months , Robust Suppression , Astria Therapeutics , Chief Executive Office , Inhibitor Deficiency , Angioedema Workshop , Principal Investigator , American Academy , Immunology Annual Meeting , Chief Business , Corporate Strategy ,